In the Appendix 4E and Annual Report some wording (page 14) seemed to allude to part of the revenue attributable to sales in Australia. "OncoSil had a cash balance of $12.2 million as at 30 June 2021. During the year, OncoSil made modest inaugural revenue from
the sale of the OncoSil™ device of $213k in Australia and New Zealand".
Ann: Appendix 4E and Annual Report, page-23
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $52.97M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.3¢ | $13.00K | 963.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 9962616 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 5510744 | 7 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| OSL (ASX) Chart |